Molecular Insight Ups IPO Terms

Molecular Insight Pharmaceuticals Inc., a Cambridge, Mass.-based developer of molecular imaging pharmaceuticals and targeted radio-therapeutics, has increased the size of its proposed IPO from $57.5 million to $86.25 million. It also has changed its co-lead underwriters from Piper Jaffray and SG Cowen to RBC Capital Markets and Jefferies & Co. The original S-1 filing came in November 2005. The company has raised over $35 million in VC funding from firms like Cerberus Capital Management and Siemens Venture Capital. www.molecularinsight.com